Inflammasomes are multiprotein complexes involved in the activation of caspase-1 and the processing of the pro-inflammatory cytokines, interleukin (IL)-1beta and IL-18 as well as the cell death mechanism of pyroptosis. The basic components of inflammasomes are a protease, caspase-1, the adaptor protein apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), and a sensor molecule, e.g. a NOD-like receptor (NLR) such NLRP1, -2 or -3, AIM2 or pyrin. Inflammasomes are activated by DAMPs such as ATP, fatty acids, DNA or PAMPs as Bacillus anthracis or flagellin. However, some inflammasomes respond to more than one type of inflammasome inducer, e.g. the NLRP3 inflammasome is assembled in response to reactive oxygen species (ROS) or ATP. 

"A Company Dedicated to Diagnosing and Treating Inflammatory Diseases"

InflamaCORE's experienced team of scientists  are dedicated to  understand the innate immune response and how inflammation can be targeted therapeutically.  The company is  advancing an innovative treatment for acute neurological insults including, stroke, brain trauma and spinal cord injury, as well as chronic CNS diseases like multiple sclerosis, Parkinson’s Disease and Alzheimer’s Disease, and also the development of tests that diagnose early onset of disease, evaluate functional outcomes and help guide treatment strategies. The combination of novel therapeutic interventions targeting inflammasome activation and biomarker discovery provides a powerful approach to assess treatments in patients with these devastating injuries and diseases.

InflamaCORE was founded in 2009 with the vision of developing novel therapeutic interventions to target abnormal inflammation following CNS injury and repair.  This starter company was formed by several University of Miami Miller School of Medicine faculty interested in the pathophysiology and treatment of brain and spinal cord injury.  Over the last several years, InflamaCORE has made significant progress in clarifying the role of the innate immune response in the pathogenesis of CNS injury.  Our scientists have discovered the molecular basis for heightened inflammasome activation after different types of CNS injury and disease, including multiple sclerosis, stroke, traumatic brain injury and spinal cord injury. InflamaCORE has developed novel biologics that target the adaptor protein ASC present in multiple inflammasomes and ASC specks that contribute to a variety of innate immune inflammatory diseases and conditions.  Blocking inflammasome assembly and ASC speck function prevents damaging inflammation in a variety of diseases and conditions.

InflamaCORE, LLC